Sun Pharma

Mumbai, India Founded: 1983 • Age: 43 yrs Listed Fortune India 500 · #53 India's Most Valuable · #10
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
Request Access
Report Incorrect Data
Page last updated

About Sun Pharma

Sun Pharma is a publicly listed company based in Mumbai (India) founded in 1983 by Dilip Shanghvi. Specialty generic pharmaceuticals and APIs are manufactured and marketed. The company has 19,801 employees. Sun Pharma has completed 19 acquisitions, including Biosynthesis, Caraco Pharmaceutical Laboratories and Chattem Chemicals. Its website sunpharma.com draws about 216 thousand monthly visits. Its Indian entity Sun Pharmaceutical Industries Limited reported revenue of ₹61,674 Cr. Its focus areas include Traditional Pharmaceuticals and Diversified.

Company details

Sun Pharma was founded in 1983 in Mumbai, India, as a specialty generic pharmaceutical entity. Formulations and active pharmaceutical ingredients are produced and distributed across therapeutic areas including psychiatry, neurology, cardiology, diabetology, gastroenterology, gynaecology, nephrology, urology, and oncology. Dosage forms encompass tablets, capsules, injectables, inhalers, ointments, creams, and liquids. In 2022, annual revenues reached 5.39 billion with net profits at 0.54 billion.

Sun Pharma is ranked #53 on the Fortune India 500 (2025) and #10 among India's most valuable companies (2025).

Recognitions & Rankings of Sun Pharma

Fortune India 500 2025 edition
Rank#53
Total income
₹54,579 Cr
Profit
₹10,929 Cr
Last year #54
India's Most Valuable Companies 2025 edition · Source: Hurun India
Rank#10
Valuation
₹4,33,880 Cr
1-year change
0%
2024 #11 2023 #14 2022 #21
  • Headquarters Mumbai, India
  • Employees 19,801
  • Founders Dilip Shanghvi
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health
  • Phone
    •••• ••••
  • Website sunpharma.com
  • Social LinkedIn X Facebook
  • Legal Name Sun Pharmaceutical Industries Limited
Operational Areas
Healthcare → Traditional Health & Nutrition
Key Metrics
  • Market Cap
    ₹4,56,953 Cr

    SUNPHARMA · NSE

  • Share Price
    ₹1,902.30

    -0.12% today

  • Revenue
    ₹58,462 Cr

    FY 2025-26 · +11.2% YoY

  • EBITDA
    ₹15,184 Cr

    Margin 26.0%

  • Net Profit
    ₹12,429 Cr

    FY 2025-26 · +8.5% YoY

  • P/E (TTM)
    37.1x

    P/B 5.1x

  • ROE
    14.8%

    ROCE 18.7%

  • Debt / Equity
    0.04

    Interest cover 2.8x

  • Employee Count
    19,801
  • Investments & Acquisitions
    Biosynthesis

    & 18 more

Board of directors of Sun Pharmaceutical Industries Limited (Sun Pharma)

Sun Pharmaceutical Industries Limited is the primary company behind Sun Pharma. The board of Sun Pharmaceutical Industries Limited currently have 8 directors; the longest-serving is Dilip Shantilal Shanghvi, appointed in 2008. 20 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Dilip Shantilal Shanghvi
DIN 00005588
Whole-time director01 Apr 200818 yrs 7 moSun Pharmaceutical Industries Limited
Pawan Kumar Goenka
DIN 00254502
Director21 May 20215 yrs 5 moSun Pharmaceutical Industries Limited
Aalok Dilip Shanghvi
DIN 01951829
Whole-time director01 Jun 20233 yrs 5 moSun Pharmaceutical Industries Limited
Rolf Karl Heinz Hoffmann
DIN 10200311
Director15 Jun 20233 yrs 4 moSun Pharmaceutical Industries Limited
Vidhi Dilip Shanghvi
DIN 06497350
Whole-time director22 May 20251 yr 5 moSun Pharmaceutical Industries Limited
Kirti Wardhaman Ganorkar
DIN 10620142
Managing Director01 Sep 20251 yr 2 moSun Pharmaceutical Industries Limited
Satyavati Berera
DIN 05002709
Director08 May 20266 moSun Pharmaceutical Industries Limited
Andreas Eugen Busch
DIN 11699735
Director12 May 20266 moSun Pharmaceutical Industries Limited

People of Sun Pharma

143 people are tracked at Sun Pharma (69 in leadership, 4 in board & advisors, 70 in team); the tracked headcount is 19,801.

NameRoleGroup
Dilip Shanghvi
Founder & Managing DirectorLeadership
Aalok Shanghvi
Executive DirectorLeadership
Nisha Ravindran
Marketing HeadLeadership
Abdul Wadud
Vertical Head, Marketing- CVS & Gastro/ GPMLeadership
Mike Garanzini
Senior Director Of Marketing, OphthalmicsLeadership
Akash Falke
Deputy General Manager MarketingLeadership
Andrea Craven
Head Of MarketingLeadership
Matthew Zinsky
Senior Director Of MarketingLeadership
Peggy Klopper
Head Of MarketingLeadership
Alok Batra
Director: Ranbaxy Pharmaceuticals Ukraine - A Sun Pharma CompanyLeadership
Indranil Sen
Regional Head - Mena, FWA & BangladeshLeadership
Sanjay Jangir
General ManagerLeadership
Miten Soni
Director, Brand MarketingLeadership
Vivek Trivedi
Head Of Supply Planning - US FactoriesLeadership
Snehal Shah
Senior General ManagerLeadership
Saurabh Varshney
CAL HeadLeadership
Nirav Shah
General ManagerLeadership
Ruchi Jha
Executive Assistant To Senior Vice PresidentLeadership
Karthik Iyer
General Manager OperationsLeadership
Nitin Joshi
G.m (head) Emerging Market- Business Development (npi- Inhouse & Licensing) & Portfolio ManagementLeadership

123 more people are available in the full profile.

Premium access

Complete people profiles for Sun Pharma

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Sun Pharma

Sun Pharma is a publicly listed company on the NSE with ticker symbol SUNPHARMA in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date14 Jul 1995
  • Listed onBSE: 524715
  • Listed entitySun Pharmaceutical Industries Limited
  • Exchange sectorHealth technology
  • ISININE044A01036
  • Share price₹1,740.80 (-1.69% on the day) · 2026-10-14
  • Market capitalisation₹424,456 Cr
  • Price to earnings34.5
  • EPS (diluted, trailing year)₹50.41
  • Dividend yield0.91%
  • Volume (last session)643,792

Financials of Sun Pharma

Exchange-reported figures of Sun Pharmaceutical Industries Limited, the listed company behind Sun Pharma (NSE: SUNPHARMA).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹58,462 Cr
+11.2% YoY
EBITDA
₹15,184 Cr
+5.4% YoY
Profit After Tax
₹12,429 Cr
+8.5% YoY
Net Worth
₹83,570 Cr
+15.7% YoY
Total Assets
₹90,020 Cr
+18.9% YoY
Total Debt
₹4,627 Cr
+95.9% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue58,46252,57848,49743,88638,65433,49832,838
Revenue growth+11.2%+8.4%+10.5%+13.5%+15.4%+2.0%-
EBITDA15,18414,40812,49311,4755,6774,1626,714
EBITDA margin+26.0%+27.4%+25.8%+26.2%+14.7%+12.4%+20.4%
Profit before tax15,11913,75211,0889,4084,4812,7995,010
Net profit12,42911,4569,9908,6056,7175,7283,961
Net profit margin+21.3%+21.8%+20.6%+19.6%+17.4%+17.1%+12.1%
EPS (₹)47.8445.5539.9135.3213.6412.1015.69
Balance sheet
Total assets90,02075,71871,31467,13153,37654,44758,774
Net worth83,57072,21863,66755,99548,01146,46345,264
Total debt4,6272,3623,2746,8861,2903,8698,315
Cash & bank11,60311,33210,5215,7705,0336,4466,488
Net working capital24,53922,74820,83516,90910,83114,13717,336
Cash flow
Cash from operations12,41914,07212,1354,9598,9856,1706,555
Cash from investing(10,405)(5,183)(763)(7,220)(5,556)407(2,225)
Cash from financing(2,513)(7,906)(6,710)2,376(5,193)(5,980)(5,715)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue16,19915,30014,61215,52114,47813,85112,95913,675
Revenue growth (YoY)+11.9%+10.5%+12.8%+13.5%+8.9%+9.5%--
Other income517724458579470464613466
EBITDA3,4754,2143,9544,4594,5273,4843,3543,693
EBITDA margin+21.6%+27.8%+27.2%+28.8%+31.4%+25.3%+26.2%+27.5%
Depreciation758739775732730701664631
Interest74.6799.6785.8978.3699.8674.8049.1451.51
Profit before tax3,1594,0993,5514,2274,1683,1733,2543,476
Tax1,1581,1888288261,0318701,094559
Net profit2,0022,9112,7243,4013,1372,3032,1612,918
EPS (₹)8.3012.1011.3014.0013.009.509.0012.10
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue20,75522,97720,27520,81215,58614,11612,532
Revenue growth-9.7%+13.3%-2.6%+33.5%+10.4%+12.6%-
EBITDA4,2776,5835,2813,4858482,1672,712
EBITDA margin+20.6%+28.7%+26.1%+16.7%+5.4%+15.4%+21.6%
Profit before tax3,7944,9763,4501,7413078563,253
Net profit2,9454,2183,0523,356(1,338)9063,018
Net profit margin+14.2%+18.4%+15.1%+16.1%-8.6%+6.4%+24.1%
EPS (₹)10.9317.6211.917.05(0.42)3.5113.38
Balance sheet
Total assets36,57636,64736,64432,64530,67835,63932,356
Net worth22,37123,90023,69423,74824,58826,93824,396
Total debt13,60511,94711,2277,7915,0747,3586,406
Cash & bank437911338421535361655
Net working capital10,19511,54910,4927,901(576)4,6035,492
Cash flow
Cash from operations6,5014,252(292)5077,636(417)1,306
Cash from investing(1,345)(251)(265)(686)(2,697)1,4521,483
Cash from financing(5,230)(3,836)474169(4,871)(1,000)(2,871)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue6,1425,7414,9245,6884,5485,5957,1796,181
Revenue growth (YoY)+35.0%+2.6%-31.4%-8.0%-11.2%+24.4%--
Other income81.0114062.9318072.7910413269.05
Total expenses4,4273,8083,5954,1883,3653,9734,1204,476
EBITDA1,7151,9331,3291,5001,1841,6223,0591,705
EBITDA margin+28.3%+34.3%+27.2%+26.5%+26.2%+29.2%+43.1%+28.5%
Depreciation316308326339336311305303
Interest277278217244248238232231
Profit before tax1,2031,4868491,0976721,1762,6541,240
Tax33237124039210843161283.81

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 11 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue16,19915,30014,61215,52114,47813,85112,95913,675
Revenue growth (YoY)+11.9%+10.5%+12.8%+13.5%+8.9%+9.5%--
Other income517724458579470464613466
EBITDA3,4754,2143,9544,4594,5273,4843,3543,693
EBITDA margin+21.6%+27.8%+27.2%+28.8%+31.4%+25.3%+26.2%+27.5%
Depreciation758739775732730701664631
Interest74.6799.6785.8978.3699.8674.8049.1451.51
Profit before tax3,1594,0993,5514,2274,1683,1733,2543,476
Tax1,1581,1888288261,0318701,094559
Net profit2,0022,9112,7243,4013,1372,3032,1612,918
EPS (₹)8.3012.1011.3014.0013.009.509.0012.10
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue58,46252,57848,49743,88638,65433,49832,838
Revenue growth+11.2%+8.4%+10.5%+13.5%+15.4%+2.0%-
Other income3,2122,1511,3906351,075859652
Total expenses43,27838,17036,00432,41032,97829,33726,124
Employee cost11,4199,9739,4298,2967,3016,8626,362
EBITDA15,18414,40812,49311,4755,6774,1626,714
EBITDA margin+26.0%+27.4%+25.8%+26.2%+14.7%+12.4%+20.4%
Depreciation2,9382,5752,5572,5292,1442,0802,053
Interest339231238172127141303
Profit before tax15,11913,75211,0889,4084,4812,7995,010
Tax3,5542,7721,4398481,076515823
Net profit12,42911,4569,9908,6056,7175,7283,961
Net profit margin+21.3%+21.8%+20.6%+19.6%+17.4%+17.1%+12.1%
EPS (₹)47.8445.5539.9135.3213.6412.1015.69
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital240240240240240240240
Reserves & surplus83,33071,97863,42755,75547,77146,22345,025
Shareholders' funds (net worth)83,57072,21863,66755,99548,01146,46345,264
Minority interest3102683,4593,3203,0553,0173,860
Secured loans0.000.000.000.000.007.83257
Unsecured loans4,6272,3623,2746,8861,2903,8618,057
Total debt4,6272,3623,2746,8861,2903,8698,315
Total liabilities90,02075,71871,31467,13153,37654,44758,774
Assets
Gross block60,32145,95044,32043,10038,70735,57935,116
Net block32,82222,58623,24824,06522,66521,55322,847
Capital work in progress3,0526,6445,3544,9731,2871,5671,220
Investments24,72318,35415,02614,82412,8499,61210,143
Inventories11,49310,2439,86810,5138,9258,9977,875
Sundry debtors15,51013,04611,24911,43910,4859,0619,421
Cash & bank balances11,60311,33210,5215,7705,0336,4466,488
Loans & advances4,3214,3173,2102,7672,7882,8082,973
Total current assets42,92738,93834,84930,48927,23127,31226,757
Total current liabilities18,38816,19014,01413,58016,40013,1759,420
Net working capital24,53922,74820,83516,90910,83114,13717,336
Total assets90,02075,71871,31467,13153,37654,44758,774
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash10,2699,2864,6244,5086,2735,6777,062
Net cash from operating activities12,41914,07212,1354,9598,9856,1706,555
Net cash from investing activities(10,405)(5,183)(763)(7,220)(5,556)407(2,225)
Net cash from financing activities(2,513)(7,906)(6,710)2,376(5,193)(5,980)(5,715)
Net change in cash(498)9834,662115(1,765)596(1,386)
Closing cash11,60311,33210,5215,7705,0336,4466,488
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+11.2%+8.4%+10.5%+13.5%+15.4%+2.0%-
EBITDA growth+5.4%+15.3%+8.9%+102.1%+36.4%-38.0%-
PBT growth+9.9%+24.0%+17.9%+110.0%+60.1%-44.1%+31.5%
Net income growth+8.5%+14.7%+16.1%+28.1%+17.3%+44.6%-
Revenue CAGR (3Y)+10.0%+10.8%+13.1%+10.2%+10.0%+8.1%+1.3%
EBITDA CAGR (3Y)+9.8%+36.4%+44.3%+19.6%+3.7%-3.7%-12.7%
Profitability & leverage
Net income margin+19.8%+20.9%+19.9%+19.5%+8.8%+6.8%+12.8%
Return on capital employed+18.7%+19.5%+17.2%+16.8%+18.0%+13.6%+9.9%
Return on net worth+14.9%+16.2%+16.1%+16.5%+14.5%+11.1%+9.7%
Debt / equity0.040.040.080.080.050.130.22
Long-term debt / equity0.000.000.010.010.010.030.04
Interest cover2.771.962.401.923.606.796.50
Efficiency & per share
Fixed asset turnover1.101.161.111.071.040.950.98
Inventory turnover5.385.234.764.524.313.974.17
Debtors turnover4.094.334.284.003.963.623.59
EPS (₹)47.8445.5539.9135.3213.6412.1015.69
Dividend per share (₹)16.0016.0013.5011.5010.007.504.00
Book value per share (₹)348.31301.00265.36233.38200.11193.65188.66
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue6,1425,7414,9245,6884,5485,5957,1796,181
Revenue growth (YoY)+35.0%+2.6%-31.4%-8.0%-11.2%+24.4%--
Other income81.0114062.9318072.7910413269.05
Total expenses4,4273,8083,5954,1883,3653,9734,1204,476
EBITDA1,7151,9331,3291,5001,1841,6223,0591,705
EBITDA margin+28.3%+34.3%+27.2%+26.5%+26.2%+29.2%+43.1%+28.5%
Depreciation316308326339336311305303
Interest277278217244248238232231
Profit before tax1,2031,4868491,0976721,1762,6541,240
Tax33237124039210843161283.81
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue20,75522,97720,27520,81215,58614,11612,532
Revenue growth-9.7%+13.3%-2.6%+33.5%+10.4%+12.6%-
Other income1,7766345533291,1971921,511
Total expenses16,47716,39514,99417,32714,73811,9499,820
Employee cost2,9112,6912,3742,1572,0011,8061,703
EBITDA4,2776,5835,2813,4858482,1672,712
EBITDA margin+20.6%+28.7%+26.1%+16.7%+5.4%+15.4%+21.6%
Depreciation1,3121,2871,6011,6011,3501,236562
Interest948954784472388268408
Profit before tax3,7944,9763,4501,7413078563,253
Tax1,17174859150.3340713.1741.86
Net profit2,9454,2183,0523,356(1,338)9063,018
Net profit margin+14.2%+18.4%+15.1%+16.1%-8.6%+6.4%+24.1%
EPS (₹)10.9317.6211.917.05(0.42)3.5113.38
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital240240240240240240240
Reserves & surplus22,13123,66023,45423,50824,34826,69924,156
Shareholders' funds (net worth)22,37123,90023,69423,74824,58826,93824,396
Secured loans0.000.000.000.000.005.416.18
Unsecured loans13,60511,94711,2277,7915,0747,3536,400
Total debt13,60511,94711,2277,7915,0747,3586,406
Total liabilities36,57636,64736,64432,64530,67835,63932,356
Assets
Gross block20,68119,20018,25217,74517,19515,8128,245
Net block7,6137,3727,7378,7129,7139,6695,229
Capital work in progress8991,0847668538291,090597
Investments12,95212,41012,43012,61315,54915,53717,362
Inventories4,3023,9343,4243,9893,4043,4232,634
Sundry debtors10,16611,7028,8347,1254,2456,5856,168
Cash & bank balances437911338421535361655
Loans & advances1,7732,2342,3164,7081,3272,3292,089
Total current assets16,67918,78114,91316,2439,51112,69911,546
Total current liabilities6,4847,2314,4218,34310,0878,0966,055
Net working capital10,19511,54910,4927,901(576)4,6035,492
Total assets36,57636,64736,64432,64530,67835,63932,356
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash493327410420351315303
Net cash from operating activities6,5014,252(292)5077,636(417)1,306
Net cash from investing activities(1,345)(251)(265)(686)(2,697)1,4521,483
Net cash from financing activities(5,230)(3,836)474169(4,871)(1,000)(2,871)
Net change in cash(74.73)165(83.82)(9.25)68.4736.23(82.26)
Closing cash437911338421535361655
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-9.7%+13.3%-2.6%+33.5%+10.4%+12.6%-
EBITDA growth-35.0%+24.7%+51.5%+310.9%-60.9%-20.1%-
PBT growth-23.8%+44.3%+98.1%+467.4%-64.1%-73.7%+352.2%
Net income growth-30.2%+38.2%-9.1%+351.0%-247.6%-70.0%-
Revenue CAGR (3Y)-0.1%+13.8%+12.8%+18.4%+14.8%+16.3%+17.7%
EBITDA CAGR (3Y)+7.1%+98.0%+34.6%+8.7%+16.1%+327.4%+187.6%
Profitability & leverage
Net income margin+12.6%+18.4%+14.1%+8.1%-0.6%+6.0%+25.6%
Return on capital employed+14.5%+16.2%+12.2%+16.3%+7.5%+3.6%+11.9%
Return on net worth+12.7%+17.8%+12.1%+13.9%-5.2%+3.5%+13.6%
Debt / equity0.550.490.400.270.240.270.27
Long-term debt / equity0.310.260.400.270.200.130.06
Interest cover31.9618.0121.3125.06-77.3228.7318.98
Efficiency & per share
Fixed asset turnover1.041.231.131.190.941.171.60
Inventory turnover5.046.255.475.634.574.664.62
Debtors turnover1.902.242.543.662.882.212.24
EPS (₹)10.9317.6211.917.05(0.42)3.5113.38
Dividend per share (₹)16.0016.0013.5011.5010.007.504.00
Book value per share (₹)93.2499.6198.7698.98102.48112.28101.68

Investments & Acquisitions by Sun Pharma

Sun Pharma has strategically engaged in corporate development activities, having acquired 19 companies. Notable acquisitions include Biosynthesis, Caraco Pharmaceutical Laboratories and Chattem Chemicals.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Innovcare
Developer of nutraceuticals and functional foods
innovcare.inMumbai, India2014Jun 2026$28.66M
Organon
Organon is focused on improving women's health globally.
organon.comJersey, United States0Apr 2026$11.75B
Checkpoint Therapeutics
Immuno-oncology treatments for solid tumors are developed and commercialized.
checkpointtx.comNew York, United States2014Mar 2025$355M
Libra Merger
Generic drugs are manufactured by Libra Merger in Israel.
Israel2023Jan 2024••••
Vivaldis
Vivaldis is engaged in providing animal healthcare solutions.
vivaldis.co.inPune, India2014Mar 2023$17.4M
Concert Pharma
Multiple drug candidates are developed for treating various diseases.
concertpharma.comLexington, United States2006Jan 2023$576M
POLA PHARMA
Regional newspapers and magazines are published and distributed locally.
pola-pharma.co.jpShinagawa, Japan2007Nov 2018$1M
Zenotech Laboratories
Generic injectables for oncology and anesthesiology are manufactured.
zenotechlab.comHyderabad, India1989Jul 2017$13.31M
Ocular Technologies
Customer experience and branding services are provided to clients.
oculartechnologies.comJohannesburg, South Africa2003Dec 2016$40M
Biosynthesis
Generic drugs are manufactured by Biosynthesis in the pharmaceutical sector.
biosintez.comFriendship, United States1955Nov 2016$64M
Premium access

Complete acquisition details for Sun Pharma

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Sun Pharma

12 dated milestones of Sun Pharma across 43 years, from founding to its latest funding, stage changes and deals.

  1. Founded Sun Pharma is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Acquisition Acquires Biosynthesis.
  4. Acquisition Acquires Ocular Technologies.
  5. Acquisition Acquires Zenotech Laboratories.
  6. Acquisition Acquires POLA PHARMA.
  7. Acquisition Acquires Concert Pharma.
  8. Acquisition Acquires Vivaldis.
  9. Acquisition Acquires Libra Merger.
  10. Acquisition Acquires Checkpoint Therapeutics.
  11. Acquisition Acquires Organon.
  12. Acquisition Acquires Innovcare.

Web traffic of Sun Pharma

The website of Sun Pharma (sunpharma.com) receives about 216K visits a month and ranks #177,160 among all websites worldwide, #5,635 in Health.

  • Monthly visits
    216K

    ▲ 6.6% vs previous month

  • Unique visitors
    99.9K

    per month

  • Global rank
    #177,160

    among all websites

  • Category rank
    #5,635

    Health · Health

Similar websites

Websites whose visitors overlap most with Sun Pharma. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Cipla
cipla.com
100%
200.9K#203,362View details
Dr. Reddy's Laboratories
drreddys.com
90%
118.8K#308,607View details
Aurobindo Pharma
aurobindo.com
80%
24.4K#1,029,164View details
Torrent Pharma
torrentpharma.com
76%
31.6K#932,209View details
Ranbaxy Laboratories
ranbaxy.com
69%
View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 40 similar websites and full traffic analytics for Sun Pharma

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 40 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Sun Pharma (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Inventia Healthcare
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 89.42 M962
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M4,050
Mankind Pharma
Pharmaceutical company engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations
1991Delhi, Delhi, IndiaUSD 367.2 MUSD 1.52 B19,419
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Sun Pharma

Government Suggests Immediate Halt On Manufacturing Licenses For Drug Companies That Don't Pass Essential Quality Tests, Licenses Will Be Restored Only After Confirmed Corrections.
Exchange Update • 6 days ago
Sun Pharma: Clarifies That Production Halt Of Eye-Care Drug Is Connected To Quality Issues Expected In August 2026, No New Updates Provided; Share Price Change Not Linked To This News.
Exchange Update • 7 days ago
Medicine Sales Growth in India Reaches 12% in October 2026, Boosted by Increased Demand for Chronic-Care Treatments.
Exchange Update • 9 days ago
Sun Pharma: Co's Ilumya Gets USFDA Approval For Active Psoriatic Arthritis, Expanding Its Biologics Portfolio Beyond Psoriasis; It's An IL-23 Inhibitor Approved For Use By Healthcare Providers Only.
Exchange Update • 12 days ago
SUNPHARMA: Q2 CONS PBT 44B RUPEES VS 42BB (YOY); CO HAS AN EXCEPTIONAL ITEM OF 12.7B RUPEES
Exchange Update • 12 days ago
SUNPHARMA: Q2 EBITDA 47.4B RUPEES VS 45.27B (YOY); Q2 EBITDA MARGIN 29.3% VS 31.27% (YOY)
Exchange Update • 12 days ago
SUNPHARMA: Q2 REVENUE 162B RUPEES VS 144.78B (YOY)
Exchange Update • 12 days ago
Sun Pharma: Reports Q2 US Sales Of $455 Million, Dropping 8.2% Compared To Last Year.
Exchange Update • 12 days ago
Sun Pharma: Raises ₹78.2 Billion But Falls Short Of ₹100 Billion Bond Goal.
Exchange Update • 19 days ago
Sun Pharma: Unloxcyt® Gains Category 2A Status In NCCN Guidelines For Patients With Advanced Skin Cancer Not Suitable For Surgery Or Radiation.
Exchange Update • 22 days ago
Premium access

Complete news archive for Sun Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Articles about Sun Pharma on our blog

Frequently Asked Questions about Sun Pharma

Sun Pharma was founded in 1983.

Sun Pharma is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Sun Pharma has 19,801 employees.

The primary company behind Sun Pharma, Sun Pharmaceutical Industries Limited, reported revenue of ₹61,674 Cr for FY 2026, up 11% year on year.

Sun Pharma was founded in 1983 in Mumbai, India, as a specialty generic pharmaceutical entity. Formulations and active pharmaceutical ingredients are produced and distributed across therapeutic areas including psychiatry, neurology, cardiology, diabetology, gastroenterology, gynaecology, nephrology, urology, and oncology. Dosage forms encompass tablets, capsules, injectables, inhalers, ointments, creams, and liquids. In 2022, annual revenues reached 5.39 billion with net profits at 0.54 billion.

Yes, Sun Pharma is publicly traded on NSE under the ticker symbol SUNPHARMA.

Sun Pharma has made 19 acquisitions, including Biosynthesis, Caraco Pharmaceutical Laboratories, and Chattem Chemicals.

Sun Pharma operates through Sun Pharmaceutical Industries Limited.

The legal entities of Sun Pharma currently have 10 directors, including Pawan Kumar Goenka, Anoop Anjanikumar Deshpande, Dilip Shantilal Shanghvi and others.

The website of Sun Pharma receives about 216 thousand visits a month and ranks #177,160 among all websites worldwide.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available